Drug Profile
Research programme: neurological disorders therapeutics - Gloriana therapeutics
Alternative Names: BrainRepair research project - Gloriana Therapeutics; EC biodelivery programme - Gloriana Therapeutics; ECB-PD; ECT-PD; Meteorin; Meteorin-like growth factors - Gloriana Therapeutics; Ns G34; NsG 0301; NsG 33Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator NsGene USA
- Developer AlzeCure; Gloriana Therapeutics; NsGene; Sanofi
- Class Analgesics; Antiepileptic drugs; Antiparkinsonians; Cell therapies; Gene therapies; Growth factors
- Mechanism of Action Glial cell line-derived neurotrophic factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Corticobasal degeneration; Motor neuron disease; Neurodegenerative disorders; Neuropathic pain; Parkinson's disease; Temporal-lobe-epilepsy
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Temporal-lobe-epilepsy in USA (Intracerebral, Implant)
- 05 Dec 2019 NsGene USA is now called Gloriana Therapeutics
- 28 Nov 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in Denmark (Intracerebral, Implant)